1 of 1
Story summary
- The FDA's fast-track drug review program, launched under U.S. President Donald Trump, faces safety concerns.
- Internal documents show delays in reviewing two drugs after a patient death and adverse event reports.
- Critics say the program risks politicizing reviews and undermining scientific standards.
- The program has expanded to 18 drugs, but only one has been approved.
